NORMOTHERMIA VERSUS HYPOTHERMIA DURING CARDIOPULMONARY BYPASS - A RANDOMIZED, CONTROLLED TRIAL

被引:77
作者
TONZ, M
MIHALJEVIC, T
VONSEGESSER, LK
SCHMID, ER
JOLLERJEMELKA, HI
PEI, P
TURINA, MI
机构
[1] UNIV ZURICH HOSP,INST CLIN IMMUNOL,INST ANASTHESIOL,CARDIOVASC SURG CLIN,ZURICH,SWITZERLAND
[2] UNIV ZURICH HOSP,INST CLIN CHEM,CH-8091 ZURICH,SWITZERLAND
关键词
D O I
10.1016/0003-4975(94)00718-M
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To evaluate the influence of perfusion temperature on systemic effects of cardiopulmonary bypass (CPB), 30 patients undergoing elective coronary artery bypass grafting were randomly assigned to either normothermic (warm, n=14, 36 degrees C) or hypothermic (cold, n=16, 28 degrees C) CPB. Serial hemodynamic measurements and blood samples were obtained before, during and after the CPB procedure. During CFB, there were no differences between both groups in the need for vasopressors (norepinephrine, phenylephrine), urinary output, or fluid balance. In the early postoperative period, normothermic CPB patients had significantly lower systemic vascular resistance and higher cardiac index measurements (mean a standard error: systemic vascular resistance, 880 +/- 27 versus 1,060 +/- 57 dyne.s.cm(-5), p = 0.025; cardiac index, 3.6 +/- 0.1 versus 2.9 +/- 0.1 L.min(-1) m(-2), p = 0.01) without differences in the administration of vasoactive drugs. Blood loss was significantly higher in patients after hypothermic CPB (median [range] body surface area: 370 [180-560] versus 490 [280-2,120] mL/m(2), p = 0.0006), with a greater need for transfusion of erythrocytes and fresh frozen plasma. Plasma levels of tumor necrosis factor and soluble tumor necrosis factor receptors increased during and after CPB, independent of perfusion temperature. This study suggests a significant influence of CPB temperature and respective perfusion management on postoperative hemodynamics and blood loss. Normothermic CPB is not associated with additional systemic adverse effects.
引用
收藏
页码:137 / 143
页数:7
相关论文
共 23 条
[1]   WARM BLOOD CARDIOPLEGIA - SUPERIOR PROTECTION AFTER ACUTE MYOCARDIAL-ISCHEMIA [J].
BROWN, WM ;
JAY, JL ;
GOTT, JP ;
HUANG, AH ;
PANCHIH ;
HORSLEY, WS ;
DORSEY, LMA ;
KATZMARK, S ;
SIEGEL, RJ ;
GUYTON, RA .
ANNALS OF THORACIC SURGERY, 1993, 55 (01) :32-42
[2]   ROLE OF CYTOKINES IN THE PATHOGENESIS OF CARDIOPULMONARY-INDUCED MULTISYSTEM ORGAN FAILURE [J].
CASEY, LC .
ANNALS OF THORACIC SURGERY, 1993, 56 (05) :S92-S96
[3]   CIRCULATING ENDOTOXIN AND TUMOR-NECROSIS-FACTOR DURING PEDIATRIC CARDIAC-SURGERY [J].
CASEY, WF ;
HAUSER, GJ ;
HANNALLAH, RS ;
MIDGLEY, FM ;
KHAN, WN .
CRITICAL CARE MEDICINE, 1992, 20 (08) :1090-1096
[4]   A RANDOMIZED STUDY OF THE SYSTEMIC EFFECTS OF WARM HEART-SURGERY [J].
CHRISTAKIS, GT ;
KOCH, JP ;
DEEMAR, KA ;
FREMES, SE ;
SINCLAIR, L ;
CHEN, E ;
SALERNO, TA ;
GOLDMAN, BS ;
LICHTENSTEIN, SV ;
CIMOCHOWSKI, GE ;
GALLAGHER, MW ;
FRANTZ, PT ;
ENGELMAN, RM .
ANNALS OF THORACIC SURGERY, 1992, 54 (03) :449-459
[5]   PLASMA TUMOR NECROSIS FACTOR LEVELS IN PATIENTS WITH PRESUMED SEPSIS - RESULTS IN THOSE TREATED WITH ANTILIPID-A ANTIBODY VS PLACEBO [J].
DEGROOTE, MA ;
MARTIN, MA ;
DENSEN, P ;
PFALLER, MA ;
WENZEL, RP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 262 (02) :249-251
[6]   ENDOTOXIN RELEASE AND TUMOR-NECROSIS-FACTOR FORMATION DURING CARDIOPULMONARY BYPASS [J].
JANSEN, NJG ;
VANOEVEREN, W ;
GU, YJ ;
VANVLIET, MH ;
EIJSMAN, L ;
WILDEVUUR, CRH .
ANNALS OF THORACIC SURGERY, 1992, 54 (04) :744-748
[7]  
KROGMANN ON, 1994, EUR HEART J S, V14, P218
[8]  
Lehot J J, 1992, J Cardiothorac Vasc Anesth, V6, P132, DOI 10.1016/1053-0770(92)90186-B
[9]  
LICHTENSTEIN SV, 1991, J THORAC CARDIOV SUR, V101, P269
[10]   PROSPECTIVE, RANDOMIZED TRIAL OF RETROGRADE WARM BLOOD CARDIOPLEGIA - MYOCARDIAL BENEFIT AND NEUROLOGIC THREAT [J].
MARTIN, TD ;
CRAVER, JM ;
GOTT, JP ;
WEINTRAUB, WS ;
RAMSAY, J ;
MORA, CT ;
GUYTON, RA .
ANNALS OF THORACIC SURGERY, 1994, 57 (02) :298-304